To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission

Ann Hematol. 2022 Nov;101(11):2545-2547. doi: 10.1007/s00277-022-04938-0. Epub 2022 Jul 29.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Sulfonamides / therapeutic use
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
  • venetoclax